Detalle Publicación

Eficacia y seguridad de distintas cepas de BCG en el tratamiento del tumor vesical en práctica clínica habitual

Autores: Unda-Urzai, M. (Autor de correspondencia); Cozar-Olmos, J. M. ; Miñana López, Bernardino; Camarero-Jimenez, J.; Brugarolas-Rossello, X. ; Zubiaur-Libano, C.; Ribal-Caparros, M. J.; Suarez-Charneco, A. J. ; Rodriguez-Tesedo, V.; Chantada-Abal, V.; Ruiz-De-Leon, C.; Carrillo-George, C.; Carballido-Rodriguez, J. ; Villacampa Aubá, Felipe
Título de la revista: ACTAS UROLOGICAS ESPAÑOLAS
ISSN: 0210-4806
Volumen: 42
Número: 4
Páginas: 238 - 248
Fecha de publicación: 2018
Resumen:
Background: The natural progression of bladder tumours (nonmuscle-invasive bladder cancer [NMIBC]) is recurrence with a high rate of progression. Bacille Calmette-Guerin (BCG) has been shown effective in reducing these rates, but there are few comparative studies between strains. Material and methods: An observational, prospective and multicentre registry studied 433 patients with a 12-month follow-up visit from 961 registered patients, assessing disease-free survival (DES), progression-free survival (PFS) cancer-specific survival (CSS) and adverse effects. We studied the Tice, Russian, Tokyo, Connaught and RIVM strains. Results: The sociodemographic data, NMIBC history, comorbidities, size, number, stage, grade, associated carcinoma in situ and transurethral resection were well balanced. DFS: There were 85 relapses (19.6%). The median DES time was 20 months. When comparing the various strains, we detected no statistically significant differences (log-rank test; P =.93). LPS: There were 33 cases of progression (7.62%). When comparing the various strains, we detected no statistically significant differences (log-rank test; P=.69). CSS: Seven patients died (1.68%). When comparing the various strains, we detected no statistically significant differences (log-rank test; P=.93). In terms of safety, 33.3% of the patients presented some type of adverse effect, mostly lower urinary symptoms (no urinary tract infections) < 48 h, > 48 h and haematuria. According to the Common Toxicity Criteria of the European Organisation for Research and Treatment of Cancer, 92.7% of the patients were grade 1. There were no statistically significant differences between the strains. Conclusions: In this intermediate analysis, the risk of recurrence, progression, specific death and safety were independent of the BCG strain employed. (C) 2017 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.